Background
Methods
Criteria for inclusion and exclusion
Search strategy
Reference screening
Methodological quality assessment for the included studies
Information extraction and analysis
Results
Procedure for study inclusion
Description of studies
Study ID | Sample size (I/C) | Gender (M/F) | Age | Intervention Group | Controlled Group | Syndrome Differentiation | Course of Treatment | Following-up | Outcomes | ||
---|---|---|---|---|---|---|---|---|---|---|---|
HAMD Mean score (SD) | Effective Rate (events/total) | Adverse Effect | |||||||||
Depression | |||||||||||
Cheng XY 2007 [7] | 33/30 | I:18/15; C:16/14 | I:37.1 ± 7.6; C:36.7 ± 8.7 | Chai Hu Shu Gan San + Fluoxetine | Fluoxetine | Y | 6 weeks | N | 6.32(2.33) vs 7.01(3.45) | NR | I: somnolence, dry mouth and sleepy; C: insomnia, blurred vision, nausea, headache. (Case unknown) |
Lin B 2011 [8] | 30/30 | I:13/17; C:15/15 | I:52.13 ± 4.31; C:50.43 ± 4.80 | Chai Hu Shu Gan San | Fluoxetine | Y | 20 days | N | 11.53(7.41) vs 13.23(6.99) | 26/30 vs 5/30 | NR |
Liu YY 2012 [9] | 31/32 | I:11/19; C:12/20 | I:40.5 ± 9.9; C:36.6 ± 15.0 | Chai Hu Shu Gan San + Venlafaxine | Venlafaxine | Y | 4 weeks | N | 5.9(4.6) vs 8(5.6) | NR | NR |
Wang RC 2013 [10] | 40/40 | I:18/22; C:21/19 | I:33.6 ± 10.75; C:34.70 ± 11.23 | Chai Hu Shu Gan San | Paroxetine | Y | 6 weeks | N | 7.21(4.23) vs 7.52(3.79) | 33/40 vs 34/40 | I: slight headache, tiredness,constipation, sweat, bitter taste; C: dry mouth, constipation, excitement and agitation, insomnia, dizziness, headache, palpitation, quiver, nausea, vomit, sexuality descent, ejaculation inhibition, female sexual lack. (Case unknown) |
Shao XQ 2016 [11] | 15/13 | I:8/7; C:7/6 | I:37.4 ± 7.53; C:36.7 ± 7.61 | Chai Hu Shu Gan San | Fluoxetine | Y | 6 weeks | 6 months | 9.51(4.84) vs 10.24(4.01) | 14/15 vs 12/13 | No adverse effect reported in intervention group;Nausea, anorexia, headache, sexual dysfunction reported in control group (Case unknown) |
Gu XX 2016 [12] | 30/30 | I:18/12 C:16/14 | I:33.1 ± 14.4 C:32.8 ± 17.1 | Chai Hu Shu Gan San + Mirtazapine | Mirtazapine | N | 8 weeks | N | 7.82(1.56) vs 15.88 (1.42) | 27/30 vs 24/30 | Appetite increased, weight gain, edema, nausea, dry mouth, sleep disorders (Case unknown) |
Hu J 2015 [13] | 48/48 | I:20/28 C:22/26 | I:38.56 ± 12.23 C:39.89 ± 11.83 | Chai Hu Shu Gan San | Paroxetine | N | 6 weeks | N | 9.65(3.44) vs C:8.98(4.32) | 43/48 vs 42/48 | NR |
Liu CY 2015 [14] | 35/34 | I:21/14C:19/15 | I:49.12 ± 7.64 C:48.46 ± 7.25 | Chai Hu Shu Gan San + Amitriptyline | Amitriptyline | Y | 3 months | N | 4.83(1.37) vs 4.79(1.02) | 33/35 vs 28/34 | constipation (I = 1 vs C = 7/34); dry mouth (I = 0 vs C = 4); dizzy(I = 1 vs C = 5);electrocardiographic abnormality (I = 1 vs C = 6) |
Deng SZ 2012 [15] | 53/48 | I:28/25; C:23/25 | NA | Chai Hu Shu Gan San + Citalopram | Citalopram | Y | 8 weeks | N | 6.07(1.86) vs 9.38(2.27) | 49/53 vs 37/48 | NR |
Song YM 2011 [16] | 30/30 | I:11/19; C:12/18 | I:46.5 ± 6.3; C:45.3 ± 7.2 | Chai Hu Shu Gan San | Fluoxetine | Y | 4 weeks | N | 14.8(3.3) vs 17.6(2.8) | 28/30 vs 24/30 | NR |
Fan QL 2008 [17] | 70/35 | I:28/42; C:13/22 | I:67.5; C:67.5 | Chai Hu Shu Gan San | Paroxetine | Y | 3 months | N | NR | 69/70 vs 29/35 | NR |
Deng GQ 2013 [18] | 30/30 | I:13/17; C:12/18 | I:38.5 ± 10.4; C:40.2 ± 12.1 | Chai Hu Shu Gan San | Paroxetine | Y | 6 weeks | N | 8.9(3.5) vs 9.7(2.8) | 24/30 vs 22/30 | NR |
Wang L 2012 [19] | 30/30 | I:12/18; C:14/16 | NA | Chai Hu Shu Gan San + Fluoxetine | Fluoxetine | Y | 4 weeks | N | NR | 28/30 vs 25/30 | Insomnia, mental tension, nausea, headache (C = 9 vs I = 3) |
Post-stroke Depression | |||||||||||
Chang XH 2010 [20] | 50/50 | I:31/19; C:28/22 | I:42–74; C:45–75 | Chai Hu Shu Gan San + Fluoxetine | Fluoxetine | Y | 28 days | N | 10.24(3.4) vs 14.2(2.7) | 48/50 vs 41/50 | NR |
Chen HH 2013 [21] | 47/47 | I:30/17; C:29/18 | I:67 ± 4; C:66 ± 5 | Chai Hu Shu Gan San | Fluoxetine | N | 4 weeks | N | 5.82(1.56) vs 6.21(1.38) | 43/47 vs 42/47 | Nausea (I = 1 vs C = 14), nodal tachycardia (I = 0 vs C = 5), stomach discomfort (I = 2 vs C = 15), dry mouth (I = 2 vs C = 18), somnolence (I = 1 vs C = 15); |
Cui Y 2016 [22] | 30/30 | I:18/12; C:16/14 | I:52.23 ± 9.90; C:50.73 ± 10.52 | Chai Hu Shu Gan San + Escitalopram Oxalate Tablets | Escitalopram Oxalate Tablets | Y | 6 weeks | N | 8.67(4.97) vs 12.4(6.97) | NR | no apparent adverse effect in both group. |
He XM 2007 [23] | 36/18 | I:21/15; C:11/7 | I:53.24 ± 6.31; C:54.36 ± 4.42 | Chai Hu Shu Gan San + Fluoxetine | Fluoxetine | N | 60 days | N | 16.41(2.56) vs 22.06(3.35) | 32/36 vs 11/18 | digestive discomfort (I = 8 vs C = 10), vegetative nerve functional disturbance (I = 10 vs C = 9); |
Huang WX 2010 [24] | 32/31 | I:17/15; C:16/15 | I:65 ± 4.6; C:61 ± 5.3 | Chai Hu Shu Gan San + Deanxit | Deanxit | Y | 8 weeks | N | 15.6(4.4) vs 16.2(4.9) | NR | I; dizziness (2 cases), constipation (1 cases); C: No adverse effect |
Huang YS 2012 [25] | 39/39 | I:22/17; C:20/19 | I:62.51 ± 7.47;C:61.93 ± 7.82 | Chai Hu Shu Gan San + Fluoxetine | Fluoxetine | Y | 3 months | N | 9.57(2.11) vs 13.08(2.58) | 35/39 vs 32/39 | I: No adverse effect; C: 6 cases with dry mouth, nausea, vomit, appetite reduced, insomnia, headache, tiredness. |
Lian Z 2009 [26] | 30/30 | I:17/13; C:16/14 | I:56.20 ± 18.6; C:54.6 ± 17.5 | Chai Hu Shu Gan San + Fluoxetine | Fluoxetine | N | 60 days | N | 6.21(2.53) vs 12.1(1.25) | 26/30 vs 24/30 | gastrointestinal discomfort (I = 6 vs C = 14), Autonomic nerve dysfunction (I = 7 vs C = 16) |
Wang GL 2009 [27] | 66/66 | I:24/40; C:28/38 | I:63.5 ± 2.3; C:64.5 ± 3.4 | Chai Hu Shu Gan San + Paroxetine | Paroxetine | Y | 6 weeks | N | 7.2(2.1) vs 10.1(1.7) | 62/66 vs 52/66 | NR |
Ji XL 2013 [28] | 30/30 | I:18/12 C:17/13 | NA | Chai Hu Shu Gan San | Fluoxetine | Y | 30 days | N | 9.1(3.2) vs 13.3(3.5) | 25/30 vs 19/30 | NR |
Zhang FH 2013 [29] | 40/40 | I:18/22 C:16/24 | I:66.3; C:65.8 | Chai Hu Shu Gan San + Deanxit | Deanxit | Y | 6 weeks | N | 14.2(2.1) vs 17.3(2.6) | 36/40 vs 31/40 | NR |
Ren MJ 2015 [30] | 36/36 | 41/31 | 58.6 ± 2.1 | Chai Hu Shu Gan San | Fluoxetine | Y | 30 days | N | 8.2(2.6) vs 14.1(2.8) | 35/36 vs 30/36 | Dry mouth, nausea, anorexia, fatigue (I = 0 vs C = 4) |
Postnatal Depression | |||||||||||
Zhao XP 2006 [31] | 45/42 | I:0/45; C:0/42 | I:29.04 ± 3.99; C:29.12 ± 4.26 | Chai Hu Shu Gan San + Fluoxetine | Fluoxetine | Y | 4 weeks | N | 9.18(5.72) vs 11.36(5.73) | 43/45 vs 39/42 | Nausea, appetite descent, anxiety, somnipathy, quiver (Case unknown). |
Zhao Y 2016 [32] | 41/42 | I:0/41; C:0/42 | I:28.94 ± 5.03; C:30.12 ± 4.3 | Chai Hu Shu Gan San + Fluoxetine | Fluoxetine | N | 8 weeks | N | 8.31(2.05) vs 13.96(2.16) | NR | Dry mouth, dizziness, nausea, tiredness, somnolence, quiver (I = 3 vs C = 10) |
Cancer and Depression | |||||||||||
Fang XH 2013 [33] | 45/45 | I:17/28; C:24/21 | I:42.3 ± 18.1; C:47.6 ± 16.9 | Chai Hu Shu Gan San | Fluoxetine | N | 6 weeks | N | 11.78(3.21) vs 13.98(2.12) | 38/45 vs 34/45 | Dry mouth (I = 2 vs C = 3), constipation (I = 2 vs C = 0), dizziness and headache (I = 3 vs C = 2),insomnia (I = 4 vs C = 1), gastrointestinal dysfunction (I = 7 vs C = 2), blurred vision (I = 2 vs C = 0) |
Epilepsy and Depression | |||||||||||
Huang XB 2015 [34] | 62/60 | 64/58 | 37.28 ± 7.29 | Chai Hu Shu Gan San | Paroxetine | N | 12 weeks | N | 17.68(1.95) vs 22.12(1.9) | 41/57 vs 25/54 | NR |
Chronic Pelvic Inflammation and Depression | |||||||||||
Li L 2006 [35] | 38/36/38 | I:0/38; C1:0/36; C2:0/38 | N/A | Chai Hu Shu Gan San | C1: Paroxetine; C2: No Intervention | N | 6 weeks | N | 17.71(3.91) vs C1:18.55(4.51); C2: 22.00(3.91) | 34/38 vs C1:28/36; C2:18/38 | NR |
Post-PCI and Depression | |||||||||||
Wang YT 2016 [36] | 30/30 | NA | NA | Chai Hu Shu Gan San | Deanxit | N | 4 weeks | N | 15.73(6.05) vs 14.77(6.84) | 25/30 vs 23/30 | NR |
COPD and Depression | |||||||||||
Yang G 2011 [37] | 40/40 | I:24/16; C:22/18 | I:62.37 ± 6.78; C:63.6 ± 7.25 | Chai Hu Shu Gan San | No Intervention | N | 4 weeks | N | 14.59(1.12) vs 20.15(1.08) | 34/40 vs 20/40 | NR |
Parkinson and Depression | |||||||||||
Ma YZ 2011 [38] | 36/32 | NA | NA | Chai Hu Shu Gan San + Sertraline Hydrochloride | Sertraline Hydrochloride | Y | 4 weeks | N | 9.2(3.6) vs 12.3(5.4) | NR | NR |
Zhou R 2016 [39] | 36/36 | I:18/18; C:16/20 | NA | Chai Hu Shu Gan San + Duloxetine | Duloxetine | Y | 4 weeks | N | 15.96(3.96) vs 20.28(3.56) | NR | Nausea (I = 2 vs C = 2), headache (I = 0 vs C = 1) |
Yang MJ 2010 [40] | 30/30 | I:18/12; C:17/13 | I:62 ± 6.53; C:62.13 ± 5.92 | Chai Hu Shu Gan San + Paroxetine | Paroxetine | Y | 8 weeks | N | 9.02(1.24) vs 13.12(2.72) | 27/30 vs 21/30 | Dry mouth (I = 2 vs C = 5); fatigue (I = 1 vs C = 3); Nausea (I = 2 vs C = 3); poor appetite (I = 4 vs C = 5); insomnia (I = 2 vs C = 5); constipation (I = 2 vs C = 5) |
Piman syndrome and Depression | |||||||||||
Qiu ZJ 2012 [41] | 36/36/36 | I:17/19; C1:16/20; C2:17/19 | I:36.17 ± 13.29; C1:36.17 ± 11.29; C2:38.83 ± 11.94 | Chai Hu Shu Gan San | C1:Deanxit; C2: No Intervention | N | 6 weeks | N | 6.42(3.68) vs C1:5.42(4.14); C2:16.03(4.34) | NR | Mouth odor, nausea, vomit, inappetence, gastrointestinal dysfunction, diarrhea, constipation in three groups, (Case unknown) |
Cerebrovascular disease and Depression | |||||||||||
Yao K 2013 [42] | 38/38 | I:20/18; C:19/19 | I:65.27 ± 8.35; C:66.31 ± 7.94 | Chai Hu Shu Gan San + Mirtazapine | Mirtazapine | Y | 4 weeks | N | 12.53(3.17) vs 15.87(3.62) | 34/38 vs 30/38 | Dry mouth, nausea, constipation (Case unknow) |
Shang GM 2014 [43] | 29/29 | I:17/12; C:16/13 | I:63.38 ± 10.21; C:62.91 ± 9.83 | Chai Hu Shu Gan San | Fluoxetine | N | 4 weeks | N | NR | 27/29 vs 23/29 | NR |
Gastroesophageal Reflux Disease and Depression | |||||||||||
Zheng YJ 2016 [44] | 43/42 | I:18/25; C:17/25 | I:32.3 ± 12.6; C:44.2 ± 7.4 | Chai Hu Shu Gan San | No Intervention | N | 8 weeks | N | 9.2(1.3) vs 14.3(1.8) | 40/43 vs 32/42 | Nausea (I = 1 vs C = 5), dry mouth (I = 0 vs C = 2), dizziness (I = 0 vs C = 4) |
Coronary heart disease and Depression | |||||||||||
Liu YH 2014 [45] | 25/24 | I:14/11; C:13/11 | I:60.7 ± 13.6; C:56.8 ± 10.2 | Chai Hu Shu Gan San | No Intervention | N | 4 weeks | N | NR | 19/25 vs 9/24 | No adverse effect reported in both groups |
Rheumatoid arthritis and Depression | |||||||||||
Chen PY 2015 [46] | 34/34 | NA | NA | Chai Hu Shu Gan San | Paroxetine | N | 6 weeks | N | 10.68(6.83) vs 19.31(7.69) | NR | NR |
Diabetes and Depression | |||||||||||
Yang YL 2013 [47] | 40/38 | I:18/22; C:15/23 | I:38.70 ± 11.10; C:37.5 ± 11.2 | Chai Hu Shu Gan San | Paroxetine | Y | 3 months | N | 14.12(7.84) vs 22.69(11.66) | 38/40 vs 28/38 | NR |
Cardiac neurosis and Depression | |||||||||||
Pei GX 2013 [48] | 60/60 | I:18/42; C:24/36 | I:42.58 ± 6.12; C:44.32 ± 4.58 | Chai Hu Shu Gan San + Deanxit | Deanxit | Y | 8 weeks | N | 11.42(3.45) vs 13.68(2.74) | 57/60 vs 53/60 | NR |